Beta-blockers in cirrhosis: Therapeutic window or an aspirin for all?  by Ferrarese, Alberto et al.
Letters to the EditorBeta-blockers in cirrhosis: Therapeutic window or an aspirin for all?
With regards to their role in early cirrhosis, we recently
described the pleiotropic effect of NSBBs and the need for their
evaluation as part of preventative strategies in patients with early
cirrhosis [9]; their potential effects include reduction in the inci-
dence of ascites, reduction in bacterial translocation, and a poten-
tial anti-angiogenic effect [10].
NSBBs may not be a risk factor per se for increased non-bleed-
ing related mortality in patients with cirrhosis and ascites. Other
acquired factors such as cirrhotic cardiomyopathy or sepsis could
be detrimental in those patients with refractory ascites undergo-
ing paracentesis. Therefore, temporary dose adjustment in the
event of sepsis or large volume paracentesis might prove more
beneﬁcial than not prescribing NSBBs in the ﬁrst place. Further
dedicated studies should evaluate NSBBs dose and their hemody-
namic consequences, to provide hepatologists with conclusive
evidence between the possible increase in mortality and the
use of NSBBs.
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We have read with interest the review article by Ge and Runyon
on the changing role of non-selective b-blockers (NSBBs) in cir-
rhosis [1]. Their role in reduction of portal hypertension is accom-
plished by lowering portal inﬂow (b1 blockade) and inducing
splanchnic vasoconstriction (b2 blockade). Risk of variceal bleed-
ing correlates also with other factors, i.e., infections and severity
of liver dysfunction, suggesting absence of a pure mechanical
model. For this reason, patients with more severe disease
(Child-Pugh Class C) should undergo primary prophylaxis even
in the presence of small varices [2].
In this paper, the authors suggested a ‘‘window hypothesis’’,
also supported by Krag and co-authors [3], according to which
NSBBs are beneﬁcial only in decompensated patients with med-
ium-large varices but not in patients with early or end-stage cir-
rhosis with refractory ascites. Their recommendation on patients
with refractory ascites is mainly based on data from a study per-
formed by Serstè and collaborators, which showed that mortality
in patients with refractory ascites was increased in those taking
NSBBs. The same group hypothesized that b-blockade could induce
counter-regulatory over-activation of the Renin-Angiotensin-
Aldosterone axis, increasing incidence of paracentesis-induced
circulatory dysfunction, which could be associated with impaired
renal function and reduced survival [4,5]. These data were not
conﬁrmed by another study on patients with ascites taking
propranolol [6]; moreover, by analyzing all published random-
ized controlled trials on prophylaxis for variceal hemorrhage,
bleeding unrelated mortality was similar between patients
on NSBBs and those treated with other therapies in primary
(277/955 vs. 287/1175; OR 0.91 95% CI 0.73 to 1.15) and
secondary prophylaxis (188/1143 vs. 225/1208; OR 0.87 95% CI
0.68 to 1.12) without heterogeneity amongst studies, while
causes of death were not different between patients on and off
NSBBs therapy. These results were conﬁrmed in the subgroup
analysis of studies with higher prevalence of ascites (>50%) [7].
Moreover the dose of propranolol should be further investi-
gated as a potential factor associated with increased mortality;
for instance, in the French study, high propranolol doses (mean
132 mg/day) could have contributed to altered haemodynamics
[8].
Furthermore, chronotropic and inotropic negative effect by
NSBBs may reduce cardiac function in patients with more severe
cirrhotic cardiomyopathy or new onset of sepsis. For instance, we
admitted a patient with alcoholic cirrhosis on the waiting list for
liver transplantation who developed spontaneous bacterial peri-
tonitis and sepsis and required large volume paracentesis
(LVP); systemic vascular resistances were severely reduced at
baseline in respect of previous procedures, and at the end of
LVP there was a further reduction of 31.2%; notwithstanding, a
counterbalancing increase of cardiac output to 12.9 L/m
(+30.9%) prevented development of hepatorenal syndrome after
LVP.
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An apology for beta blockers
To the Editor:
We read with interest the recent review on beta-blockers in cir-
rhosis by Ge and Runyon [1]. This topic is of great importance, as
non-selective beta blockers are a pharmacological mainstay in
the management of patients with cirrhosis; the amount of evi-
dence has been increasing substantially since the ﬁrst published
trial of their use in the prevention of variceal bleeding [2], partic-
ularly in recent years.
In their review, the authors dedicate a sub-heading to ‘‘Beneﬁts
of beta-blocker therapy’’. This consists of only two paragraphs, in
which some trials of beta blockade for primary prevention of vari-
ceal bleeding are discussed. In the last line, the use of beta blockers
in secondary prophylaxis of variceal bleeding is just about men-
tioned, and reference to a table (Table 1) is made. Table 1, titled
‘‘Key studies supporting beta-blocker usage’’, only lists trials of
beta blockers for the primary prevention of variceal bleeding. For
reasons best known to them (but not to us), the authors chose to
completely ignore mountains of evidence for a wide range of
non-selective beta blockers in patients with cirrhosis, including
such trivialities as effects on mortality, risk of decompensation,
development of ascites, renal failure, encephalopathy, and bacte-
rial infections. This includes true landmark studies [3], the results
ofwhichhavebothbeen replicated [4] andextensivelydiscussed in
the literature [5]. Similarly, the vast majority of the wide-ranging
pharmacological effects of beta-blockers, particularly non-haemo-
dynamic effects [5,6], are largely ignored, exceptionmade for a sin-
gle mentioning of bacterial translocation in Fig. 1.
The authors then embark on a lengthy discussion of ‘‘adverse
effects of beta-blocker therapy’’. The sub-heading itself spans 5
paragraphs (more than twice the length of the beneﬁts!), but the
successive elaboration on the inherent evil of beta blockers (vari-
ously termed ‘‘The differential effect of beta-blockers in cirrhosis’’,
‘‘Blood pressure and survival’’, ‘‘Beta-blockers in refractory
ascites’’, and ‘‘Additional challenges of beta-blocker therapy’’)
cover several pages. In this section, the authors discuss at length
the possible adverse effects of beta blockers, quoting studies in
patients without liver disease published mainly between 1969
and 1990. It is also rather puzzling that the use of beta blockers
in arterial hypertension, cardiac failure, and acute coronary syn-
dromes is discussed, as this debate has little importance to their
use in liver disease. Interestingly, had the authors applied a bit
more dedication to their ‘‘holistic’’ approach to beta-blockers, they
might have stumbled across other rather informative (and much
more recent) studies outlining the safety (and signiﬁcant beneﬁt)
of beta blockers in COPD [7,8], peripheral vascular disease [9],
and diabetes [10]. Table 2, titled ‘‘Key studies suggesting potential
harm from beta-blocker usage’’ clearly is meant to mirror Table 1
in size and importance. It strikes us that of the ‘‘key’’ studies men-
tioned in this table, the ﬁrst only shows an increased likelihood of
adverse events with beta blockers as compared to placebo (a ﬁnd-
ing which is hardly surprising), while the second study quite
amusingly only investigates the prognostic importance of the
cardiac index in cirrhosis without making use of beta blockers.
The other two quoted studies are a heavily debated observational
study and a cross-over study looking at paracentesis-induced
circulatory dysfunction in 10 patients. By contrast, even the com-
pletely unrepresentative choice of key studies in Table 1 entirely
consists of controlled trials.
At this point it is of little further consequence to mention
other surprising ﬁndings, such as the space given to the discus-
sion of midodrine and ACE inhibitors in a review on beta blockers,
and the fact that studies on midodrine are quoted as evidence
‘‘conﬁrming the importance of maintaining cardiac output in
patients with advanced cirrhosis’’ – indeed, midodrine is a vaso-
constricting agent and does not increase cardiac output, but has
actually been found to decrease it [11].
Finally, in their fervour against beta-blockers, the authors go
as far as providing ‘‘recommendations’’ for the use of beta block-
ers in cirrhosis, the evidence for which is as feeble as the discus-
sion leading up to it. Needless to say, these are to our mind very
hazardous statements, which might well lead to a reduction in
the use of this class of highly effective and very cheap agents,
which have rightly been termed ‘‘the Hepatologist’s Aspirin’’ [12].
Sadly, we feel that a great opportunity to discuss this crucial
topic in Hepatology has been missed, as this review is
ill-conceived and poorly researched, leading to conclusions which
might be far more harmful than any effect beta blockers might
have in patients with cirrhosis.
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